Search IRMD
IRADIMED CORP
Nasdaq · CIK 1325618
Last close85.4
Daily change+0.10 (0.12%)
10 Years gain+430.92%
Dividends TTM1.27 (+92.42%)
Dividend yield1.49%
Fundamental Analysis
IRMD · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
82.8Momentum
64.9Acceleration
64.1Confidence
91.0Annual Revenue13
Quarterly Revenue42
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth18.6 / 25
Quality17.0 / 25
Capital Efficiency19.6 / 20
Balance Sheet15.0 / 15
Shareholder Economics7.6 / 10
Forward Indicators5.0 / 5
Signals
Operating leverageOperating margin improved by 2.981 percentage points.
ROIC expansionROIC improved by 2.5809 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM14.57%OK
Revenue CAGR 3Y16.28%OK
Gross Margin76.64%OK
Operating Margin32.42%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC31.39%OK
Incremental Operating Margin 3Y39.36%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.36%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $83.81M | $64.32M | $26.15M | $24.95M | $17.18M | 76.75% | 31.2% | 20.5% | 53.11% | 12.85M |
| 2025 FY Dec 31, 2024 | $73.24M | $56.35M | $21.97M | $25.62M | $17.62M | 76.94% | 29.99% | 24.06% | 61.89% | 12.78M |
| 2024 FY Dec 31, 2023 | $65.56M | $50.16M | $20.04M | $13.47M | $6.02M | 76.5% | 30.56% | 9.19% | 84.81% | 12.72M |
| 2023 FY Dec 31, 2022 | $53.30M | $41.28M | $15.63M | $10.04M | $9.22M | 77.45% | 29.32% | 17.3% | 95.73% | 12.64M |
| 2022 FY Dec 31, 2021 | $41.81M | $32.05M | $9.82M | $11.26M | $10.78M | 76.65% | 23.48% | 25.77% | 86.62% | 12.59M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $84.06M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-051402, 0001104659-25-105538 |
| Revenue Growth TTM | 14.57% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-051402, 0001104659-25-105538 |
| Revenue CAGR 3Y | 16.28% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-024691 |
| Revenue CAGR 5Y | 21.45% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-024691 |
| Gross Profit CAGR 3Y | 15.93% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-024691 |
| Operating Income Growth | 26.18% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001628280-26-051402, 0001104659-25-105538 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 76.64% | Gross Profit / Revenue | OK | 0001628280-26-051402, 0001104659-25-105538 |
| Operating Margin | 32.42% | Operating Income / Revenue | OK | 0001628280-26-051402, 0001104659-25-105538 |
| ROIC | 31.39% | NOPAT / Average Invested Capital | OK | 0001628280-26-051402, 0001104659-25-105538 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-051402 |
| Current Ratio | 9.46x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $6.53 | Revenue / Diluted Shares | OK | 0001628280-26-051402, 0001104659-25-105538 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |